Recent Updates
Recently added Catalysts
VSTM Positive Sentiment

Verastem Oncology Reports Third Quarter 2026 Financial Results and Highlights Recent Business Updates

Thursday, November 5, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Verastem Oncology reported its third quarter 2026 financial results, showcasing progress with VS-7375, an oral KRAS G12D inhibitor. The company highlighted promising U.S. clinical data that demonstrates the drug's efficacy as a monotherapy. This advancement reflects Verastem's commitment to developing treatments for RAS/MAPK pathway-driven cancers.

Market Sentiment Analysis

POSITIVE FACTORS

  • Significant progress with VS-7375 reported.
  • First U.S. clinical data shows efficacy.
  • Company committed to advancing new medicines.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+193%
120-day peak, hindsight
Typical move
9.4%
average across 10 past catalysts
Cash runway
~6 mo
High dilution risk
Lead asset
VS-7375
Phase 2 · Pancreatic Ductal Adenocarcinoma

Full Press Release Details

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today reported financial results for the third quarter ended September 30, 2026, and highlighted recent business progress. “During the third quarter, we made significant progress with VS-7375, our potential best-in-class oral KRAS G12D (ON/OFF) inhibitor. Our first U.S. clinical data established a new monotherapy efficacy

Frequently Asked Questions

What were Verastem's Q3 2026 financial results?

Verastem reported its financial results for Q3 2026, highlighting business progress.

What is VS-7375?

VS-7375 is a potential best-in-class oral KRAS G12D inhibitor.

What did the U.S. clinical data show?

The U.S. clinical data established efficacy for VS-7375 as a monotherapy.

What is Verastem's focus?

Verastem is focused on advancing medicines for RAS/MAPK pathway-driven cancers.

ShareAdd on Google
Tags: VSTM Verastem Oncology VS-7375 KRAS G12D biopharmaceuticals financial results
Last updated: Nov 5, 2026

Biotech snapshot

Cash runway
$136M liquidity · $15M/mo burn
~6 mo
High dilution risk
Lead asset
VS-7375Phase 2
Pancreatic Ductal Adenocarcinoma →

Catalyst track record

+193%
best trade around VSTM's most recent catalyst

Peak hindsight return over a 120-day window, across 10 tracked FDA/PDUFA catalysts for VSTM.

See every catalyst's timing & PoA →